OLR1 and non-small cell lung carcinoma: To understand the impact of the immunosuppressive cells in the response to ICIs, the percentage of MDSCs, both PMN(Lox1+)- and M-MDSCs, was evaluated in 30 NSCLC patients treated with ICIs as first-line treatment (Fig. 5).